肌醇 Inositol × 胰島素阻抗

結論:證據支持但有警示

Multiple independent meta-analyses spanning 898 to 2230 participants consistently show inositol reduces HOMA-IR (WMD around -1.

B 🟡 B 初步證據 附警語發布 ⚠️ medium — moderate promotional content
⚠️ 標記 🇹🇼 台灣在地警示

Multiple independent meta-analyses spanning 898 to 2230 participants consistently show inositol reduces HOMA-IR (WMD around -1.21) and fasting insulin (around -4.74 microU/mL), and a 7-RCT pooled analysis found 4 g/day myo-inositol cut gestational diabetes incidence by roughly 70 percent (RR 0.30). This direction-consistent effect across many trials supports more than a C grade. However, three factors hold it back from A: every measured outcome is a surrogate marker (HOMA-IR, fasting insulin, fasting glucose) with no primary clinical insulin-resistance endpoint; the 2024 International PCOS Guideline meta-analysis rated GRADE certainty Very Low and called the evidence limited and inconclusive with no advantage over metformin; and the large NiPPeR RCT (n=1729) found no glycemic benefit when inositol was started preconception in a general population, indicating population and timing strongly modulate the effect. Professional societies (ADA, Endocrine Society) are silent and neither Mayo Clinic nor Harvard maintains an inositol fact sheet, so high-quality independent endorsement is absent. On the totality of evidence a moderate, consistent but surrogate-bound and certainty-limited body of work justifies grade B at its lower bound.

⚖️

評分透明度

所有分數由 7 層證據引擎計算,過程公開可查
原始分數 0.63
D
C
B
A
S
← 反證據 / 無效有效 / 強證據 →
最終評級
B · 附警語發布
信心度
77%
證據方向大致一致
證據層級
E2
多篇高品質統合分析(≥2 篇一致)

各層「支持此療效」的程度

分數越低=該層越不支持
L5 臨床機構權威立場
0.40
L1 Examine國際基準
0.50
L3 機轉生理合理性
0.65
L11 AI 複核獨立判讀
0.65
L2 PubMed原始文獻
0.85
不支持 中性 / 混合 支持
查看完整決策路徑(audit trail)
  1. compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.633
  2. tier_from_score — 依分數區間映射至 tier letter
  3. apply_hec_rules — 高品質 SR/MA 顯示 positive (4 篇 > 0 negative)
  4. tier_strict_requirement_check — Tier 條件達標,未降階
  5. detect_disputes — 偵測到 0 個 hard + 0 個 soft dispute
  6. decide_status — 依 tier + dispute 結果決定 status

Inositol supplementation efficacy in improving key cardiometabolic and anthropometric indices: a GRADE-assessed systematic review and meta-analysis of randomized controlled trials
PMID: 41163174 2025 統合分析 n = 898
結論:Inositol supplementation across 18 RCTs significantly reduced HOMA-IR (WMD -1.21, 95% CI -1.58 to -0.85, p<0.001) and fasting insulin (WMD -4.74 μU/mL, 95% CI -6.16 to -3.32, p<0.001); fasting glucose also fell (WMD -7.25 mg/dL, 95% CI -10.98 to -3.52, p<0.001).
效應量:WMD HOMA-IR -1.21; fasting insulin -4.74 μU/mL; fasting glucose -7.25 mg/dL
前往 PubMed
Myo-inositol effects in women with PCOS: a meta-analysis of randomized controlled trials
PMID: 29042448 2017 統合分析 n = 496
結論:Across 9 RCTs (247 cases, 249 controls) myo-inositol significantly decreased fasting insulin (SMD -1.021 μU/mL, 95% CI -1.791 to -0.251, p=0.009) and HOMA index (SMD -0.585, 95% CI -1.145 to -0.025, p=0.041).
效應量:SMD fasting insulin -1.021 μU/mL; HOMA index -0.585
前往 PubMed
Inositol for Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis to Inform the 2023 Update of the International Evidence-based PCOS Guidelines
PMID: 38163998 2024 統合分析 n = 2,230
結論:Across 30 trials (2230 participants; 19 pooled) myo-inositol plus folic acid reduced HOMA-IR versus folic acid (MD -1.24, 95% CI -1.50 to -0.99) but GRADE certainty was Very Low; versus metformin no difference (MD -0.08, 95% CI -0.57 to 0.41, Low certainty). Authors concluded evidence is limited and inconclusive.
🟠 品質有限 效應量:MD HOMA-IR -1.24 (vs folic acid, Very Low certainty); -0.08 (vs metformin)
前往 PubMed
Inositol Nutritional Supplementation for the Prevention of Gestational Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
PMID: 35889788 2022 統合分析 n = 1,321
結論:Across 7 RCTs (1321 participants) 4 g/day myo-inositol lowered GDM incidence (RR 0.30, 95% CI 0.18-0.49, p<0.00001) and reduced fasting glucose (MD -4.20 mg/dL), 1-hour glucose (MD -8.75) and 2-hour glucose (MD -8.59 mg/dL, all p<0.00001).
效應量:RR GDM 0.30; fasting glucose MD -4.20 mg/dL
前往 PubMed
Myo-Inositol, Probiotics, and Micronutrient Supplementation From Preconception for Glycemia in Pregnancy: NiPPeR International Multicenter Double-Blind Randomized Controlled Trial
PMID: 33782086 2021 隨機對照試驗 n = 1,729
結論:In 1729 women planning conception, the myo-inositol-enriched formulation did NOT lower maternal glycemia at 28 weeks and did not reduce GDM incidence; it did reduce preterm birth. Contrasts with smaller at-risk-population trials.
⚠️ 廠商資助 效應量:No significant effect on 28-week glycemia or GDM incidence
前往 PubMed

L4a US FDA
中性
Inositol is recognized as Generally Recognized As Safe (GRAS) for use as a nutrient supplement; affirmed under 21 CFR 184.1370. 來源↗
L4b EU EFSA
中性
L4c UK NHS
中性
A commercially available supplement called Inofolic, which is a combination of Myo Inositol and folic acid, has shown benefit in initial studies to improve the metabolic defect in PCOS and make menstrual cycles more regular. 來源↗
L4d TW TFDA / 衛福部
中性
嬰兒配方食品及較大嬰兒配方輔助食品之檢驗值應符合中華民國國家標準(CNS)所定之標準。 來源↗
L4e WHO
中性
Minimum 4 mg/100 kcal of myo-inositol; Guidance Upper Level (GUL) 40 mg/100 kcal. [Codex Standard for Infant Formula and Formulas for Special Medical Purposes Intended for Infants, CODEX STAN 72-1981] 來源↗

L5a NIH Office of Dietary Supplements
謹慎
L5b Mayo Clinic
未表態
— 本適應症無對應資料
L5c Cleveland Clinic
謹慎
L5d Harvard Health
未表態
— 本適應症無對應資料
L5e Specialty Society (condition-mapped)
未表態

PTT · Dcard · Mobile01 彙整自公開論壇討論,非統計抽樣,僅反映社群風向。
廣告 / 業配密度 中度
📍立場總覽

台灣社群討論多集中在多囊/備孕脈絡(胰島素阻抗為其成因),鄉民實測多反映改善排卵與血糖,整體偏正面但屬經驗談,業配品牌推薦文偏多。

💬社群實感

多數正面(集中於多囊/備孕族群,反映改善排卵與血糖代謝;非多囊純胰島素阻抗討論較少)

破解迷思 社群最常見的 4 個誤解
事實以為肌醇只有多囊患者能吃(實際一般備孕女性也可補充)
事實以為肌醇水溶性所以完全無副作用、可無限量吃(過量仍可能腹脹腹瀉)
事實懷孕後仍持續吃肌醇(社群常誤傳沒差,實際多建議懷孕後停用以免子宮收縮疑慮)
事實不分劑型隨便買即可(社群其實偏好 myo-inositol 與 D-chiro 40:1 比例)
🩹 社群通報的副作用
  • 腹脹
  • 腹瀉
  • 腸胃不適(多反映於高劑量或片劑,改粉劑或分次服用可緩解)
🏷️ 社群熱議品牌

依論壇被提及頻率,非銷售或品質排序。

  • 活力媽媽倍韻
  • BHK's 孕媽咪肌醇
  • GNC 肌醇
  • iHerb 海外品牌(Jarrow / NOW 等)

⚠️ 列出僅代表「TW 社群討論度高」,不代表本站推薦或背書。本站不販售任何產品、無導購連結。

查看代表討論串 ↗

L10a · 廠商行銷話術 行銷語言
💬 通路如何宣傳

倍韻肌醇每顆含肌醇480毫克、葉酸100微克、維他命D3,一盒60顆售價NT$789元;建議肌醇每日用量1200~4000毫克

代表來源 ↗
L10b · TFDA 法定身份 官方認定

食品廣告若涉及不實、誇張或易生誤解,可處新臺幣4萬元以上400萬元以下罰鍰;涉及醫療效能者,可處60萬元以上500萬元以下罰鍰

來源 ↗

  • 強化生活型態介入(飲食加運動,目標減重 5–7%)
  • 中等強度規律運動(每週 150 分鐘)
  • Metformin(二甲雙胍)
PMID 100% 反查全部經 NCBI Entrez 驗證
🔬 5 篇 L2 文獻 經多層 sub-agent 獨立評估
🇹🇼 含台灣社群分析L10c PTT / Dcard / Mobile01
aggregated_at: 2026-06-01 claim_version: v25 engine_version: v1.0 claim_id: CLM-COND-insulin-resistance-INT-inositol-001
查看 ClaimReview 結構化資料 (JSON-LD)
{
  "@context": "https://schema.org",
  "@type": "ClaimReview",
  "url": "https://gpt-dict.com/claim/CLM-COND-insulin-resistance-INT-inositol-001/",
  "datePublished": "2026-06-01",
  "author": {
    "@type": "Organization",
    "name": "gpt-dict.com",
    "url": "https://gpt-dict.com"
  },
  "claimReviewed": "肌醇能改善胰島素阻抗",
  "inLanguage": "zh-TW",
  "itemReviewed": {
    "@type": "Claim",
    "appearance": []
  },
  "reviewRating": {
    "@type": "Rating",
    "ratingValue": 3,
    "bestRating": 5,
    "worstRating": 1,
    "alternateName": "🟡 B 初步證據"
  }
}